Raynovent’s Global-First Biweekly GLP-1/GIP Looking Solid In Topline Obesity Readout
Raynovent's first-in-class, biweekly injected GLP-1/GIP dual agonist shows 22% body weight reduction at highest dose at 52 weeks in China Phase III trial.
Scrip - October 12, 2026

AdvaMed Urges Copyright Office To Reject Renewal Of Medical Device Repair Exemption
AdvaMed is urging the US Copyright Office not to renew an exemption allowing independent servicers to repair medical devices. AdvaMed cites intellectual-property, safety and cybersecurity concerns, while Trimedx argues the exemption helps ensure timely repairs and hospitals choice.
Medtech Insight - October 9, 2026

CLIA Proposal Codifies Existing Remote Flexibilities While Adding New Digital-Data Requirements
A proposed CMS and CDC rule would codify remote review of digital lab data, ease 2023 personnel qualification standards and add CLIA requirements for digital images. Test reports also would have to carry the lab’s CLIA number and certificate name.
Medtech Insight - October 9, 2026

FDA Clears Motivista For Schizophrenia’s Negative Symptoms, But Coverage Remains Unsettled
FDA cleared Click Therapeutics’ Motivista, a smartphone adjunct for schizophrenia’s negative symptoms. Click says state Medicaid comes first, but the trial gain was modest and Medicare eligibility is unresolved as it readies a launch without Boehringer Ingelheim.
Medtech Insight - October 9, 2026

NDIN Guidance, Drug Exclusion Provision On FDA To-Do List – ‘Old’ Ingredient List Is Industry Job
ODSP director Cara Welch discussed NDIN guidance, drug exclusion provision, “old” ingredient list, defining dietary substances allowed for use in supplements and elimination of self-affirmed GRAS during Council for Responsible Nutrition conference.
HBW Insight - October 12, 2026

Kyorin Set To Transfer To Japanese Joint Venture
A joint venture agreement has been executed that will see Daito Pharmaceutical, Meiji Seika Pharma and the Development Bank of Japan create an entity to take control of Kyorin Pharmaceutical’s generic drug business in Japan.
Generics Bulletin - October 9, 2026

Sandoz Sees Reversal As Appeals Court Finds United Therapeutics Remodulin Restriction Procompetitive
United Therapeutics has won on antitrust grounds at the Third Circuit, with the court finding its Remodulin cartridge exclusivity was procompetitive despite acknowledging the firm "understood – and even desired" the restrictions would hinder Sandoz's generic launch.
Generics Bulletin - October 9, 2026

Value Added: Viatris Spotlights 505(b)(2) Assets As It Shells Out $1.65bn For Pacira
Marking another step in its push towards innovative higher-margin products, Viatris has agreed to pay $1.65bn for Pacira BioSciences, gaining access to its 505(b)(2) non-opioid pain products Exparel and Zilretta that are expected to be complementary to Viatris’ filed fast-acting meloxicam candidate.
Generics Bulletin - October 9, 2026

Moderna-Merck’s Intismeran Exposes The Personalized Medicine Infrastructure Gap
Moderna and Merck's individualized neoantigen therapy intismeran autogene has put personalized mRNA cancer treatment on the path to market. At LSX USA, panelists cautioned that manufacturing, diagnostics, regulation and reimbursement may not be ready.
In Vivo - October 9, 2026